JP2020519230A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020519230A5 JP2020519230A5 JP2018564966A JP2018564966A JP2020519230A5 JP 2020519230 A5 JP2020519230 A5 JP 2020519230A5 JP 2018564966 A JP2018564966 A JP 2018564966A JP 2018564966 A JP2018564966 A JP 2018564966A JP 2020519230 A5 JP2020519230 A5 JP 2020519230A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- protein according
- sequence
- peptide
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020001507 fusion proteins Proteins 0.000 claims 21
- 102000037865 fusion proteins Human genes 0.000 claims 21
- 102100025680 Complement decay-accelerating factor Human genes 0.000 claims 11
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 claims 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 241000700605 Viruses Species 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 5
- 230000003834 intracellular effect Effects 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- 230000003248 secreting effect Effects 0.000 claims 4
- 125000006850 spacer group Chemical group 0.000 claims 4
- 210000004899 c-terminal region Anatomy 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 244000309459 oncolytic virus Species 0.000 claims 2
- 241000711404 Avian avulavirus 1 Species 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 241000287828 Gallus gallus Species 0.000 claims 1
- 101100386242 Homo sapiens CD55 gene Proteins 0.000 claims 1
- 108091092195 Intron Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 210000001161 mammalian embryo Anatomy 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762504120P | 2017-05-10 | 2017-05-10 | |
| US62/504,120 | 2017-05-10 | ||
| PCT/US2018/032018 WO2018209052A1 (en) | 2017-05-10 | 2018-05-10 | Enveloped virus resistant to complement inactivation for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020519230A JP2020519230A (ja) | 2020-07-02 |
| JP2020519230A5 true JP2020519230A5 (enExample) | 2021-05-20 |
| JP7161940B2 JP7161940B2 (ja) | 2022-10-27 |
Family
ID=64105722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018564966A Active JP7161940B2 (ja) | 2017-05-10 | 2018-05-10 | がんの治療のための、補体不活性化に耐性のエンベロープウイルス |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11274141B2 (enExample) |
| EP (1) | EP3621635A4 (enExample) |
| JP (1) | JP7161940B2 (enExample) |
| KR (3) | KR20250118857A (enExample) |
| CN (1) | CN109414483B (enExample) |
| AU (1) | AU2018265258B2 (enExample) |
| BR (1) | BR112018075281A2 (enExample) |
| CA (1) | CA3026892A1 (enExample) |
| IL (1) | IL263979B2 (enExample) |
| MX (1) | MX2018015599A (enExample) |
| WO (1) | WO2018209052A1 (enExample) |
| ZA (1) | ZA201808040B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7165717B2 (ja) | 2017-03-15 | 2022-11-04 | パンディオン・オペレーションズ・インコーポレイテッド | 標的免疫寛容 |
| MX2019013517A (es) | 2017-05-24 | 2020-08-17 | Pandion Operations Inc | Inmunotolerancia dirigida. |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| CN112759654A (zh) * | 2019-11-06 | 2021-05-07 | 深圳普菲科生命科技有限公司 | 一种病毒囊膜蛋白装配系统及其方法和应用 |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| AU2022227480A1 (en) * | 2021-02-26 | 2023-09-14 | Sillajen, Inc. | Oncolytic virus and use thereof |
| CN113736810B (zh) * | 2021-09-08 | 2024-05-24 | 苏州因特药物研发有限公司 | 构建体、载体、蛋白、细胞、制备方法、产品及应用 |
| KR20240003051A (ko) * | 2022-06-29 | 2024-01-08 | 신라젠(주) | Cd55 및 cd59를 동시 발현하는 항암 바이러스 |
| AU2023338427A1 (en) * | 2022-09-07 | 2025-04-03 | Sillajen, Inc. | Novel use of oncolytic virus |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5374548A (en) * | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| PT1486211E (pt) | 1993-04-30 | 2009-02-02 | Wellstat Biologics Corp | Composições para tratamento do cancro utilizando vírus |
| JPH10313865A (ja) * | 1997-05-15 | 1998-12-02 | Deinabetsuku Kenkyusho:Kk | ヒト補体制御因子が呈示されたベクター |
| EP1030928A1 (en) | 1997-11-21 | 2000-08-30 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Development of viruses resistant to inactivation by the human complement system |
| AP1968A (en) | 1997-12-22 | 2009-04-30 | Univ Tennessee Res Corp | Recombinant rhabdovirus containing a heterologous fusion protein. |
| EP1071705A2 (en) * | 1998-04-02 | 2001-01-31 | Rigel Pharmaceuticals, Inc. | Peptides causing formation of compact structures |
| AU4246900A (en) | 1999-04-15 | 2000-11-02 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| EP2292259A3 (en) * | 2002-11-15 | 2011-03-23 | MUSC Foundation For Research Development | Complement receptor 2 targeted complement modulators |
| EP1784506B1 (en) | 2004-07-21 | 2010-08-25 | Dana-Farber Cancer Institute, Inc. | Lentiviral vectors and uses thereof |
| JP5050198B2 (ja) | 2006-09-05 | 2012-10-17 | 国立大学法人大阪大学 | ヒト補体制御因子発現遺伝子およびその利用 |
| WO2008118258A2 (en) * | 2007-02-06 | 2008-10-02 | Genizon Biosciences Inc. | Genemap of the human genes associated with adhd |
| KR20090122465A (ko) * | 2007-03-01 | 2009-11-30 | 어드벤스드 비젼 테라피스, 인코포레이티드 | 염증성 질환의 치료 |
| US8877896B2 (en) | 2008-02-15 | 2014-11-04 | Tufts University | Compositions, methods and kits for modeling, diagnosing, and treating complement disorders |
| JP2014516517A (ja) | 2011-04-29 | 2014-07-17 | キージーン・エン・フェー | グリホサート耐性強化 |
| CA2833931C (en) | 2011-05-05 | 2021-05-04 | Wellstat Immunotherapeutics, Llc | Complement factor b analogs and their uses |
| CN110078831A (zh) * | 2011-12-01 | 2019-08-02 | 圆祥生命科技股份有限公司 | 补体和vegf途径的蛋白质抑制剂及其使用方法 |
| FI3888674T3 (fi) * | 2014-04-07 | 2024-07-02 | Novartis Ag | Syövän hoito käyttäen kimeeristä anti-cd19-antigeenireseptoria |
| EP3143134B1 (en) | 2014-05-15 | 2020-10-28 | National University of Singapore | Modified natural killer cells and uses thereof |
| RS61907B1 (sr) * | 2015-04-06 | 2021-06-30 | Subdomain Llc | Polipeptidi koji sadrže de novo vezujući domen i njihova primena |
| GB201507119D0 (en) | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic Acid Construct |
| CN107708741A (zh) | 2015-06-12 | 2018-02-16 | 免疫医疗公司 | 用嵌合抗原受体(car)构建体和表达car构建体的t细胞(car‑t)或nk细胞(car‑nk)进行的疾病疗法 |
| EP3458576A4 (en) | 2016-05-19 | 2020-03-25 | Turnstone Limited Partnership | PSEUDOTYPIZED ONCOLYTIC RHABDOVIRUS AND THEIR USE IN COMBINATION THERAPY |
-
2018
- 2018-05-10 CA CA3026892A patent/CA3026892A1/en active Pending
- 2018-05-10 BR BR112018075281-9A patent/BR112018075281A2/pt unknown
- 2018-05-10 IL IL263979A patent/IL263979B2/en unknown
- 2018-05-10 WO PCT/US2018/032018 patent/WO2018209052A1/en not_active Ceased
- 2018-05-10 EP EP18798575.9A patent/EP3621635A4/en active Pending
- 2018-05-10 AU AU2018265258A patent/AU2018265258B2/en active Active
- 2018-05-10 MX MX2018015599A patent/MX2018015599A/es unknown
- 2018-05-10 KR KR1020257024807A patent/KR20250118857A/ko active Pending
- 2018-05-10 KR KR1020187037869A patent/KR102662049B1/ko active Active
- 2018-05-10 KR KR1020247013722A patent/KR102839445B1/ko active Active
- 2018-05-10 US US16/303,729 patent/US11274141B2/en active Active
- 2018-05-10 CN CN201880002553.7A patent/CN109414483B/zh active Active
- 2018-05-10 JP JP2018564966A patent/JP7161940B2/ja active Active
- 2018-11-28 ZA ZA2018/08040A patent/ZA201808040B/en unknown
-
2022
- 2022-02-18 US US17/674,990 patent/US20220169701A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020519230A5 (enExample) | ||
| JP7250878B2 (ja) | 新規多価ナノ粒子に基づくワクチン | |
| ES2307550T3 (es) | Di-u oligomero de un di-, tri-,tetra- o pentametro de proteinas de fusion recombinantes. | |
| HRP20200871T1 (hr) | Izmjenjeni rsv f proteini i postupci njihove uporabe | |
| JP2019514373A5 (enExample) | ||
| JP2015509707A5 (enExample) | ||
| US20220169701A1 (en) | Enveloped Virus Resistant to Complement Inactivation for the Treatment of Cancer | |
| CN104342453A (zh) | 含基因工程抗体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用 | |
| HRP20190799T1 (hr) | Imunocitokini na bazi il-15 i sushi domene il-15r alfa | |
| HRP20221531T1 (hr) | Pripravci faktora viii i postupci dobivanja i korištenja istih | |
| KR20190056382A (ko) | 안정화된 그룹 2 인플루엔자 헤마글루티닌 줄기 영역 삼량체 및 그의 용도 | |
| JP2014073123A (ja) | パラミクソウイルス科（Ｐａｒａｍｙｘｏｖｉｒｉｄａｅ）ファミリーのウイルスのＮタンパク質−対象タンパク質の融合タンパク質 | |
| CN111500631B (zh) | 用于病毒疗法的新型流感病毒载体 | |
| CN114213548B (zh) | 同时诱导抗多种病毒的免疫应答的方法 | |
| JP2019530441A5 (enExample) | ||
| RS63526B1 (sr) | Vakcine za virus gripa i njihove upotrebe | |
| CN105143251B (zh) | 流感核蛋白疫苗 | |
| WO2022043449A1 (en) | Vaccines based on an antigen protein fused to a nanostructuring scaffold | |
| WO2017041739A1 (zh) | 改造的白介素12及其在制备治疗肿瘤药物中的用途 | |
| JP2016520534A5 (enExample) | ||
| RU2008138536A (ru) | Химерные вакцинные антигены против вируса классической чумы свиней | |
| JP2013529178A5 (enExample) | ||
| CA2991213A1 (en) | Recombinant virus like particles using bovine immunodeficiency virus gag protein | |
| KR101525180B1 (ko) | 인플루엔자 바이러스 항원의 세포표면 발현벡터 및 이에 의해 형질전환된 미생물 | |
| CA2823297C (en) | Non-natural mic proteins |